## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($92.51)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 2, Bearish: 1)

**1. Revvity Inc.: Quiet Re?Rating Story in a Volatile Diagnostics Market**
- Source: AD HOC NEWS | 20251230T140835 | Bullish | Relevance: 100%
- Revvity Inc., a life-sciences and diagnostics company, is undergoing a quiet rerating as it reinvents itself post-PerkinElmer divestiture. The company has been tightening its portfolio, integrating acquisitions, and focusing on genomics, diagnostics, and analytical technologies. Investors are slowly becoming more constructive, with the stock showing a gradual uptrend driven by improved earnings visibility and strategic reset.

**2. Revvity Inc. Stock Finds Its Footing as Investors Weigh Diagnostics Demand and AI Ambitions**
- Source: AD HOC NEWS | 20251230T010807 | Somewhat-Bullish | Relevance: 100%
- Revvity Inc. shares have experienced a volatile year but are now treading water as investors assess the diagnostics specialist's post-spin-off strategy, AI-enabled lab tools, and uneven demand in life sciences. The company's one-year performance shows a slight loss for long-term holders, contrasting with broader market gains, reflecting a repricing of its risk-reward profile and a transition period. Analysts maintain a "Buy" or "Overweight" stance, foreseeing mid-teens upside potential, as Revvity focuses on expanding its diagnostics footprint, deepening life sciences tools, and leveraging digital and analytical capabilities for future growth.

**3. Revvity Inc.: Quiet Re?Rating Story in a Volatile Diagnostics Market**
- Source: AD HOC NEWS | 20251230T141625 | Bullish | Relevance: 100%
- Revvity Inc. is undergoing a quiet but significant rerating in the volatile life-sciences and diagnostics market. The company, which emerged from PerkinElmer's divestiture, has focused on tightening its portfolio and convincing investors of a deserving higher multiple for its genomics, diagnostics, and analytical technologies. Wall Street sentiment is shifting from cautious neutrality to constructive endorsement, with analysts seeing the company as undervalued given its strategic reset and focus on recurring revenue streams.

**4. Revvity, Inc. Faces Valuation Shift Amid Declining Sales and Rising Costs**
- Source: Markets Mojo | 20251230T115933 | Bearish | Relevance: 100%
- Revvity, Inc., a small-cap Pharmaceuticals & Biotechnology company, has experienced a shift in its valuation grade from attractive to very expensive. This change is attributed to declining net sales and operating profit over the past five years, alongside rising raw material costs and a high debt-equity ratio. The company's financial metrics, including a P/E ratio of 33 and a modest dividend yield of 0.32%, reflect these challenges.

**5. Revvity Inc. Stock Finds Its Footing as Investors Weigh Diagnostics Demand and AI Ambitions**
- Source: AD HOC NEWS | 20251230T001052 | Somewhat-Bullish | Relevance: 100%
- Revvity Inc. shares have found a cautious equilibrium after a volatile year, with investors re-evaluating the company's post-spin-off strategy, AI-enabled lab tools, and varying demand in life sciences. The stock has underperformed broader market benchmarks over the past year but analysts remain cautiously constructive, seeing mid-teens upside potential. Revvity's future growth hinges on its transformation into a data-driven partner, expanding its diagnostics footprint, deepening life sciences tools, and integrating digital and analytical capabilities.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $115 | $105 | +10% |
| 2025-12-15 | Wells Fargo | $107 | $102 | +5% |
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +2.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.63 indicates undervaluation relative to growth. Forward P/E 18.4x stretched relative to 8% growth. Analyst sentiment positive (2 raises, avg +7%, $109 target (+12%)). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.4B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 7.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.63 |
| Forward P/E | 18.4 |
| Current P/E | 19.8 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.5% to 0.1% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). RSI neutral at 48. OFD pattern: +MUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.12% (CS: 64) | Neutral |
| RSI_14 | 48.4 | Neutral |
| MACD Histogram | -0.47 | Bearish |
| vs SMA20 | 0.982x | Below |
| vs SMA50 | 1.004x | Above |
| vs SMA200 | 1.031x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $97.43
- **Stop Loss:** $92.51 (5.0% risk)
- **Target:** $102.35 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 268
- **Position Value:** $26,111.24
- **Portfolio %:** 26.11%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk sentiment as markets process hawkish Fed minutes. VIX at 14.33 remains calm despite Fed's single rate cut guidance for 2026, while normal yield curve (+59bps) and solid breadth (57.5%) suggest healthy market structure. Focus on quality names with defensive tilt as year-end approaches.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*